• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ARID1A 通过表观遗传沉默 RRM2 促进胰腺癌对吉西他滨的化疗敏感性。

ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.

机构信息

Department of Vascular Surgery, Xinzhou People's Hospital, Xinzhou hospital affiliated to Shanxi Medical University, The Tenth Clinical Medical College of Shanxi Medical University, Xinzhou, Shanxi.

People's Republic of China, Department of Radiotherapy and Oncology, Wuhan Sixth Hospital and Affiliated Hospital of Jianghan University, Wuhan, People's Republic of China;, Email:

出版信息

Pharmazie. 2022 Sep 1;77(7):224-229. doi: 10.1691/ph.2022.1881.

DOI:10.1691/ph.2022.1881
PMID:36199183
Abstract

Pancreatic cancer is one of the most common malignancies with very poor prognosis due to its broad resistance to chemotherapy. ARID1A, a subunit of SWI/SNF complex, is involved in pancreatic carcinogenesis through epigenetic silencing of oncogenes. In this study, we aimed to explore whether ARID1A was implicated in the gemcitabine resistance in pancreatic cancer patients via regulating RRM2. We examined the effect of ARID1A depletion on the gemcitabine sensitivity in pancreatic cancer cells and explored the role of RRM2 in ARID1A-mediated pancreatic cancer cells chemosensitivity to gemcitabine. We found that Knockout of ARID1A led to gemcitabine resistance in pancreatic cancer cells, effect of which could be reversed by RRM2, a gemcitabine resistance related gene. ARID1A decreased the transcription of RRM2, and directly bound to the promoter of RRM2. Moreover, expression of RRM2 was negatively correlated with ARID1A in pancreatic cancer tissues. Thus, ARID1A-mediated RRM2 epigenetic suppression is crucial for enhancement of pancreatic cancer chemosensitivity to gemcitabine, and ARID1A could be used as a biomarker to guide the gemcitabine chemotherapy of pancreatic cancer.

摘要

胰腺癌是最常见的恶性肿瘤之一,由于其对化疗的广泛耐药性,预后极差。ARID1A 是 SWI/SNF 复合物的一个亚基,通过表观遗传沉默癌基因参与胰腺癌的发生。在本研究中,我们旨在通过调节 RRM2 来探讨 ARID1A 是否参与胰腺癌患者对吉西他滨的耐药性。我们研究了 ARID1A 缺失对胰腺癌细胞对吉西他滨敏感性的影响,并探讨了 RRM2 在 ARID1A 介导的胰腺癌细胞对吉西他滨化疗敏感性中的作用。我们发现 ARID1A 的敲除导致胰腺癌细胞对吉西他滨产生耐药性,而 RRM2(一种与吉西他滨耐药相关的基因)可逆转这种耐药性。ARID1A 降低了 RRM2 的转录水平,并直接与 RRM2 的启动子结合。此外,在胰腺癌组织中,RRM2 的表达与 ARID1A 呈负相关。因此,ARID1A 介导的 RRM2 表观遗传抑制对于增强胰腺癌细胞对吉西他滨的化疗敏感性至关重要,ARID1A 可以作为指导胰腺癌吉西他滨化疗的生物标志物。

相似文献

1
ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.ARID1A 通过表观遗传沉默 RRM2 促进胰腺癌对吉西他滨的化疗敏感性。
Pharmazie. 2022 Sep 1;77(7):224-229. doi: 10.1691/ph.2022.1881.
2
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.let-7a 前体的差异加工影响胰腺癌中的 RRM2 表达和化学敏感性:LIN-28 和 SET 癌蛋白的作用。
PLoS One. 2013;8(1):e53436. doi: 10.1371/journal.pone.0053436. Epub 2013 Jan 15.
3
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.血管抑制素2通过原癌基因Jun依赖的核糖核苷酸还原酶调节亚基M2反式激活降低胰腺癌细胞对吉西他滨的化疗敏感性。
Mol Cancer. 2017 Mar 21;16(1):66. doi: 10.1186/s12943-017-0619-6.
4
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.miR-20a-5p 通过靶向胰腺癌细胞中的 RRM2 调节吉西他滨化疗敏感性,并可作为吉西他滨为基础的化疗的预测因子。
Biosci Rep. 2019 May 7;39(5). doi: 10.1042/BSR20181374. Print 2019 May 31.
5
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.靶向核糖核苷酸还原酶M2亚基的RNA干扰增强胰腺腺癌对吉西他滨的化疗敏感性。
Oncogene. 2004 Feb 26;23(8):1539-48. doi: 10.1038/sj.onc.1207272.
6
E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.E2F2 通过调控细胞周期和上调 RRM2 的表达增强胰腺癌对吉西他滨的化疗耐药性。
Med Oncol. 2022 Jun 18;39(9):124. doi: 10.1007/s12032-022-01715-x.
7
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).藤黄酸通过降低核苷酸还原酶亚单位 M2(RRM2)的表达来增强吉西他滨在胰腺癌中的疗效。
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107. doi: 10.1186/s13046-017-0579-0.
8
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.抑制SRC酪氨酸激酶可损害人胰腺腺癌细胞对吉西他滨的固有耐药性和获得性耐药性。
Clin Cancer Res. 2004 Apr 1;10(7):2307-18. doi: 10.1158/1078-0432.ccr-1183-3.
9
Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.用一种新型葡萄糖转运体抑制剂靶向沃伯格效应以克服胰腺癌细胞中的吉西他滨耐药性。
Carcinogenesis. 2014 Oct;35(10):2203-13. doi: 10.1093/carcin/bgu124. Epub 2014 May 30.
10
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.吉西他滨耐药性以及与人类胰腺癌细胞中吉西他滨转运和代谢相关的分子标志物。
Br J Cancer. 2007 Feb 12;96(3):457-63. doi: 10.1038/sj.bjc.6603559. Epub 2007 Jan 16.

引用本文的文献

1
Molecular interplay of ARID1A in gastrointestinal cancers.ARID1A在胃肠道癌症中的分子相互作用
Med Oncol. 2025 Aug 23;42(10):442. doi: 10.1007/s12032-025-03014-7.
2
ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.ARID1A基因缺失减弱了肺腺癌对EGFR-TKI治疗的反应。
Front Pharmacol. 2025 May 20;16:1582005. doi: 10.3389/fphar.2025.1582005. eCollection 2025.
3
Tumor energy metabolism: implications for therapeutic targets.肿瘤能量代谢:治疗靶点的意义。
Mol Biomed. 2024 Nov 29;5(1):63. doi: 10.1186/s43556-024-00229-4.
4
RRM2 promotes liver metastasis of pancreatic cancer by stabilizing YBX1 and activating the TGF-beta pathway.RRM2通过稳定YBX1并激活转化生长因子-β(TGF-β)信号通路促进胰腺癌肝转移。
iScience. 2024 Aug 31;27(10):110864. doi: 10.1016/j.isci.2024.110864. eCollection 2024 Oct 18.